Key Highlights

  • Nexalin Technology shares are trading at $7.13 in Thursday's session, up 66.63%.
  • The company signed a definitive 10-year exclusive distribution and local Manufacturing agreement covering Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador and Venezuela.
  • The distributor must place a binding initial order for 10 Nexalin Sync devices, with a clinical pilot in Brazil targeted within 90 days.
  • Nexalin is entitled to per-device compensation and royalties on locally made disposable electrodes, at no Capital cost to the company.

Brazil Deal Turns a Pre-Revenue Story Into a Commercial One

Nexalin Technology (NASDAQ:NXL) is soaring in Thursday's session after announcing a definitive distribution agreement for its Nexalin Sync neurostimulation device, which has Brazilian regulatory approval for anxiety, depression and insomnia. The Houston-based medical device company develops non-invasive deep brain stimulation technology for mental health conditions.

The agreement names Inovanexa Medical Technologies as exclusive distributor across seven countries with a combined population of more than 300 million. It carries an initial 10-year term with successive 10-year renewals subject to performance, and it replaces a letter of intent signed in February.

Only Ten Devices Are Binding So Far

The distributor is required to place a binding initial order for 10 devices, with five delivered immediately and a clinical pilot in Brazil targeted within 90 days. A structured pricing framework covers the first 100 devices, but the distributor is not obligated to buy beyond the initial order.

That distinction matters. The release cautions that purchase orders beyond the first may not materialize and that exclusivity depends on the distributor meeting performance requirements, including minimum Revenue thresholds.

Local Manufacturing Is Designed to Be Capital-Light

After the first 30 devices are purchased, the distributor must build a local manufacturing Facility in Brazil at its own cost. Nexalin would receive fixed compensation for each locally made device and a Royalty on every disposable electrode sold, while keeping ownership of its intellectual property and supplying the encrypted circuit boards the devices need.

CEO Mark White described the agreement as the shift from a pre-revenue research company to a revenue-producing distribution business.

A Spike From a Low Base Still Leaves the Stock Far Below Its Highs

Even after the surge, shares trade well below their 52-week high of $60.00, in a range that begins at $4.00. The 77.8% anxiety response rate behind the Brazilian approval came from a single-site trial, the company has a history of operating losses, and it still awaits a U.S. FDA De Novo decision. Any revenue from the agreement is still ahead.